Du et al., “The spike protein of SARS-CoV—a target for vaccine and therapeutic development,” Microbiology, vol. 7, pp. 226-236 (Mar. 2009). Engelmayer et al., “Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion”, J Immunol., 163...
the p7.5 promoter. Immediate early genes were defined as being expressed in the period spanning the first hour of the viral infection cycle. (Assarsson et al., Kinetic analysis of a complete poxvirus transcriptome reveals an immediate
Single MVA-SARS-2-ST/N vaccination in K18-hACE2 mice induced robust protection against lethal respiratory SARS-CoV-2 challenge infection 28 days later. The protective outcome of MVA-SARS-2-ST/N vaccination correlated with the activation of SARS-CoV-2-neutralizing antibodies (nA...
However, MVA-SARS-2-ST consistently elicited higher amounts of S1-, S receptor binding domain (RBD), and SARS-CoV-2 neutralizing antibodies in both vaccination protocols. Overall, we found very comparable immune responses following short- or long-interval immunization. Thus, our results suggest ...
Previously, we used this platform to develop two COVID-19 candidate vaccines, targeting the full-length spike (S) protein of SARS-CoV-2 [19,20]. One vaccine, MVA-SARS-2-S, expressed the native form of the S protein [19], whereas the second vaccine, MVA-SARS-2-ST, expressed a ...
Intramuscular MVA-ST immunization resulted in protection from disease and severe lung pathology. Importantly, this protection was correlated with a potent activation of SARS-CoV-2 specific T-cells and neutralizing antibodies. Our results suggest that MVA vector vaccines merit further evaluation in ...
(MVA)-T7pol expression system to establish a workflow to identify immunogens when a new pathogen emerges, generate candidate vaccines, and test their immunogenicity in an animal model. By using this system, we detected severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) ...